Ana Fortuño Gil-rekin lankidetzan egindako argitalpenak (57)

2020

  1. NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

2017

  1. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

  2. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

2015

  1. Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis

    Free Radical Biology and Medicine, Vol. 86, pp. 352-361

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

2013

  1. A synthetic peptide from transforming growth factor-β1 Type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats

    Antioxidants and Redox Signaling, Vol. 19, Núm. 14, pp. 1607-1618

  2. Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis

    Clinical Science, Vol. 125, Núm. 6, pp. 291-300

  3. The senescence-accelerated mouse prone-8 (SAM-P8) oxidative stress is associated with upregulation of renal NADPH oxidase system

    Journal of Physiology and Biochemistry, Vol. 69, Núm. 4, pp. 927-935

2012

  1. Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats

    Oxidative Medicine and Cellular Longevity

  2. Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress

    Journal of Hypertension, Vol. 30, Núm. 2, pp. 315-326

  3. Two variants in the Fibulin2 gene are associated with lower systolic blood pressure and decreased risk of hypertension

    PLoS ONE, Vol. 7, Núm. 8

2011

  1. Relación entre las fases precoces de la enfermedad renal y el síndrome metabólico

    Revista Espanola de Cardiologia, Vol. 64, Núm. 5, pp. 373-378

  2. The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes

    Frontiers in Bioscience - Elite, Vol. 3 E, Núm. 4, pp. 1467-1474

  3. ¿el síndrome metabólico en España necesita más estudios descriptivos o más evidencia de su implicación en prevención secundaria? Respuesta

    Revista Espanola de Cardiologia

2010

  1. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications

    Journal of Hypertension, Vol. 28, Núm. 9, pp. 1944-1950

  2. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein Kinase C: Potential clinical implications in hypertension (Hypertension (2009) 54 (744-750))

    Hypertension

  3. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2219-2226

  4. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension (Clinical Science (2009) 116, (233-240))

    Clinical Science

2009

  1. Increased CD74 expression in human atherosclerotic plaques: Contribution to inflammatory responses in vascular cells

    Cardiovascular Research, Vol. 83, Núm. 3, pp. 586-594

  2. Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients

    Journal of Hypertension, Vol. 27, Núm. 7, pp. 1420-1430